Your browser doesn't support javascript.
loading
Changes in Liver Stiffness and Markers of Liver Synthesis and Portal Hypertension following Hepatitis C Virus Eradication in Cirrhotic Individuals.
Armandi, Angelo; Rosso, Chiara; Troshina, Giulia; Pérez Diaz Del Campo, Nuria; Marinoni, Chiara; Nicolosi, Aurora; Caviglia, Gian Paolo; Saracco, Giorgio Maria; Bugianesi, Elisabetta; Ciancio, Alessia.
Afiliação
  • Armandi A; Department of Medical Sciences, University of Turin, 10126 Turin, Italy.
  • Rosso C; Metabolic Liver Disease Research Program, I. Department of Medicine, University Medical Center of the Johannes Gutenberg-University, 55131 Mainz, Germany.
  • Troshina G; Department of Medical Sciences, University of Turin, 10126 Turin, Italy.
  • Pérez Diaz Del Campo N; Department of Medical Sciences, University of Turin, 10126 Turin, Italy.
  • Marinoni C; Department of Medical Sciences, University of Turin, 10126 Turin, Italy.
  • Nicolosi A; Department of Medical Sciences, University of Turin, 10126 Turin, Italy.
  • Caviglia GP; Department of Medical Sciences, University of Turin, 10126 Turin, Italy.
  • Saracco GM; Department of Medical Sciences, University of Turin, 10126 Turin, Italy.
  • Bugianesi E; Department of Medical Sciences, University of Turin, 10126 Turin, Italy.
  • Ciancio A; Division of Gastroenterology, Città Della Salute e Della Scienza University-Hospital, 10100 Turin, Italy.
Biology (Basel) ; 11(8)2022 Aug 02.
Article em En | MEDLINE | ID: mdl-36009789
ABSTRACT
The advent of direct antiviral agents (DAAs) has radically changed the natural history of hepatitis C virus (HCV) chronic liver disease. Even patients with cirrhosis may display improvements in liver function or features of portal hypertension following viral eradication. The aim of this study was to assess whether a HCV cure would lead to improvements in cirrhotic patients using simple, readily available tools in clinical practice, together with liver stiffness (LS) measurement. This is a retrospective study of cirrhotic patients with cured HCV infection, with or without previous decompensation. Clinical and biochemical parameters as well as LS measurements were collected before antiviral treatment with DAAs and after 6 months following sustained virological response. Hepatic synthesis was assessed by serum albumin levels. Portal hypertension was indirectly assessed by platelet count. Liver function was determined by the CHILD score. A total of 373 cirrhotic patients with successful HCV eradication were retrospectively included. After 6 months of follow-up, a significantly higher proportion of patients showed improved liver function, shifting from the CHILD B/C to CHILD A group, (71.4%, p < 0.001). Similarly, LS improved from a median of 19.3 kPa (14.7−27) at the baseline vs. a median of 11.6 (7.7−16.8 kPa) at follow-up (p < 0.001). The proportion of patients who showed improved hepatic synthesis was 66.0%, which was statistically different when compared to that of patients who had a worsened condition (0.3%) (p < 0.001). Moreover, when classifying the cohort according to the RESIST-HCV score, we found that a significant proportion of patients shifted into the "low risk" group following DAA treatment (52% baseline vs. 45.6% at follow-up, p = 0.004). Even in the decompensated patients, LS improved from 1.6 to 2-fold from the baseline. Antiviral treatment is effective in improving indirect signs of hepatic synthesis and portal hypertension. Similarly, the LS values displayed significant improvements, even in decompensated patients.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article